Adverse effects of Imatinib in patients with chronic myeloid leukemia

• Hajar Masrour,
• Sanaa Bouchnafati,
• Rim Hanini,
• Widad Rhandour,
• Mounia Bouzayd,
• Laila Abarkan,
• Anas Oudrhiri,
• Latifa Lerhrib,
• Fallah Eddine Tohir,
• Maha Ouazzani Naoual Oubelkacem,
• Noufissa Alami Drideb,
• Zineb Khammar Rhizlane Berrady

Affiliations

Hajar Masrour

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Sanaa Bouchnafati

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Rim Hanini

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Widad Rhandour

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Mounia Bouzayd

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Laila Abarkan

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Anas Oudrhiri

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Latifa Lerhrib

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Fallah Eddine Tohir

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Maha Ouazzani Naoual Oubelkacem

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Noufissa Alami Drideb

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco

Zineb Khammar Rhizlane Berrady

Internal Medicine and Onco-hematology department, University Hospital Hassan II, Fes, Morocco